Haohong Pharmaceutical: ISO & Patents in Pharma Intermediates
Industry Context: The Rising Need for Verified Intermediates
The global pharmaceutical intermediates market was valued at approximately USD 37.04 billion in 2025, with oncology drug intermediates accounting for a 37.20% share of industry revenue. As drug developers and generic manufacturers push toward faster time‑to‑market, the quality and compliance of upstream intermediates have become critical decision factors. Sourcing active pharmaceutical intermediates from a supplier that can demonstrate both product integrity and regulatory adherence reduces risk across the entire supply chain.
Haohong Pharmaceutical: A Supplier Built on Certification and IP Protection
Haohong (Qihe) Pharmaceutical Technology Co., Ltd is a specialized R&D and custom production company headquartered in Shandong, China, focusing on innovative APIs and pharmaceutical intermediates. For buyers in the research‑to‑evaluation stage, Haohong offers verifiable credentials that address key procurement concerns. Its leading product, the Abemaciclib Intermediate (a key building block for breast‑cancer oncology drugs), is backed by multiple utility model patents and an ISO 9001:2015 quality management system.
Patented Production Equipment and Methodology
Haohong has secured four utility model patents from the China National Intellectual Property Administration that directly cover the Abemaciclib Intermediate and its manufacturing equipment:
| Patent Number | Scope | Issue Date | Expiry |
|---|---|---|---|
| 202520639784.6 | Refining & mixing production equipment | 2025-04-24 | 2035-04-24 |
| 202521268255.6 | Special production equipment | 2026-05-26 | 2035-05-26 |
| 202521280279.3 | General production equipment | 2026-05-27 | 2035-05-27 |
| 202521269185.6 | Abemaciclib Intermediate product itself | 2026-05-28 | 2035-05-28 |
These patents ensure that the manufacturing processes, mixing equipment, and the intermediate itself are legally protected under Chinese national standards for pharmaceutical machinery and mechanical equipment. For international buyers, this registered intellectual property provides an additional layer of confidence in the supplier’s technical capabilities and commitment to process innovation.
ISO 9001:2015 Quality Management – A Global Standard
Beyond IP, Haohong’s Abemaciclib Intermediate (product ID 3707) is covered by an ISO 9001:2015 Quality Management System Certificate (certificate number NO:174Q240545R0S), issued by Shandong Guojian Certification Co., Ltd., valid until November 2027. This certification applies globally and confirms that the company’s research, development, and production processes meet the requirements of GB/T19001-2016 (equivalent to ISO 9001:2015).
In practice, this means every batch of the Abemaciclib Intermediate undergoes rigorous quality control including chromatography (HPLC/GC), structural identification, heavy‑metal and residual‑solvent testing, and microbiological analysis. The QMS also covers the full production chain from raw material intake to final packaging and batch traceability.
Application in Oncology Drug Synthesis
The Abemaciclib Intermediate is a critical precursor for manufacturing the CDK4/6 inhibitor Abemaciclib, used in hormone‑receptor‑positive, HER2‑negative breast cancer therapy. Haohong supplies this intermediate in multiple forms including 4‑Bromo‑2,6‑difluoroaniline (CAS 1868-81-7), 5‑[(4‑Ethylpiperazin‑1‑yl)methyl]pyridin‑2‑amine (CAS 398565-53-2), and other key fragments. Each intermediate is produced with a purity ≥98% (HPLC/GC) and stored under controlled conditions (2–8°C, sealed, protected from light) to maintain stability during transit. The company provides custom synthesis from gram to hundreds of kilograms, supporting both early‑stage research and commercial‑scale production.
Market Trend Analysis and Comparison with Traditional Suppliers
The pharmaceutical intermediates industry is rapidly consolidating around suppliers that can offer documented compliance. Traditional suppliers without formal certifications or patents may expose buyers to risks such as batch inconsistency, impurity variability, and lack of process improvement traceability. In contrast, Haohong’s ISO 9001 certification and patented equipment directly address these pain points. An honest limitation: the patents are currently effective only in China, and the ISO certification, while globally recognised, does not replace a full GMP audit for API manufacturing. However, for the research‑to‑evaluation stage, these credentials provide a solid baseline for supplier qualification.
Future Outlook
As regulatory bodies such as the FDA (ICH Q7) and EU (REACH) tighten requirements for upstream intermediates, the value of certified, patent‑protected supply sources will increase. Haohong is positioned to expand its certification portfolio and extend its intellectual property protection to additional markets. With an annual production capacity of 1,000 tons and exports to the US, Europe, Japan, India, and Bangladesh, the company is scaling up while maintaining the quality and compliance backbone that serious buyers rely on.
Frequently Asked Questions
This article is for informational purposes. For detailed specifications and documentation, please refer to the official company brochure.